A small product line, an enormous legal exposure
Dow Corning Corporation entered Chapter 11 on May 15, 1995, facing thousands of breast-implant lawsuits. The Michigan company was much larger than that product: formed in 1943 by Dow Chemical Company and Corning Incorporated, it produced silicones for many uses. A 1995 court opinion recorded nearly $2 billion in 1994 sales and the company’s statement that breast implants represented less than 1% of sales in their highest-sales year, 1991. A product’s revenue share offered little protection against the financial consequences of claims involving years of past sales. [1]
The same opinion distinguished several allegations: recipients claimed systemic illnesses, while other claims concerned mechanical failures such as rupture. By early 1995, the company faced more than 19,000 individual lawsuits and 45 proposed class actions. These were claims and allegations, not 19,000 findings of causation or wrongdoing. Their scale nevertheless created a problem that could not be understood from current implant sales alone. [1]
The first global settlement did not hold
Before bankruptcy, manufacturers and claimants had attempted a broad resolution through the federal multidistrict proceeding in Alabama. A Federal Judicial Center case study describes a proposed $4.2 billion global settlement, including up to $2 billion from Dow Corning. Claims arrived in numbers far above the parties’ expectations, and the arrangement collapsed. Individual litigation continued to threaten a much larger and less predictable exposure. [2]
The study reports more than $200 million in defense costs in 1994 and roughly 90 implant cases set for state-court trials as the company approached bankruptcy. Chapter 11 placed the dispute into a collective process involving injury claimants, commercial creditors and other affected groups. Bankruptcy Judge Arthur Spector initially handled the case. The financial objective was to establish a workable reorganization and a way to resolve liabilities, rather than requiring thousands of separate cases to determine the company’s future one judgment at a time. [2]
A plan took nine years to become effective
The bankruptcy court confirmed the amended joint reorganization plan on November 30, 1999. Appeals and further litigation followed; the plan finally became effective June 1, 2004. The arrangement offered qualifying claimants different routes: settlement through an administrative facility or litigation against a separate litigation facility. Claims and administrative costs were paid through a trust. [3]
The funding agreement established a maximum aggregate payment of $3.172 billion, subject to a $2.35 billion net-present-value limit measured at the June 2004 effective date. Present value translated payments made at different times into a common-date amount, using the agreement’s 7% annual discount rate. The headline amount was therefore neither a single check paid in 2004 nor proof that every dollar of the maximum would ultimately be distributed. Annual funding ceilings, insurance proceeds and actual claims affected the payment sequence. [3]
How a claimant moved through the settlement
The settlement agreement defined specific benefit options. Eligible breast-implant claimants could qualify for an implant-removal payment, a rupture payment, and either a covered-condition payment or an expedited-release payment. Each depended on the applicable qualification rules; the categories were not automatic awards simply for having filed a lawsuit. The claims administrator applied the agreement and its claims-resolution procedures, with supporting documentation and review mechanisms. [4]
The agreement also separated base payments from possible premium payments. Certain additional rupture and disease payments depended on a court determination that sufficient money remained under the plan’s safeguards. This structure linked the timing of extra compensation to the adequacy of the fund for other allowed claims. Accepting payment also carried a release of claims against specified parties. The bargain exchanged individualized litigation for defined eligibility, payment and finality rules; meeting a settlement category did not itself establish a general scientific conclusion about implants. [4]
The medical evidence and the settlement answered different questions
In 1999, the Institute of Medicine reviewed the safety evidence. It identified local and surgical complications as substantial concerns and found that the available studies did not support the claimed association with immunologic or autoimmune diseases. Its discussion also emphasized limitations in the evidence and the importance of informed consent. That historical assessment helps explain why a large compensation arrangement cannot simply be read as a finding that every alleged systemic condition was caused by silicone implants. [5]
It would be equally misleading to turn that conclusion into a claim that implants are risk-free. The FDA’s current risk discussion describes rupture, capsular contracture and possible further surgery, as well as breast-implant-associated lymphoma and reports of other malignancies. It says it has not detected an association with connective-tissue disease, breast cancer or reproductive problems, while acknowledging reported systemic symptoms whose causes remain poorly understood. Those distinctions concern medical evidence; the bankruptcy agreement governed which claims qualified for its negotiated payments. [6]
The business continued while the claims system remained
The industrial company’s ownership changed long before the settlement process ended. On June 1, 2016, Dow Chemical Company announced that it had completed the transaction making it the full owner of Dow Corning’s silicones business. It reported that business had more than $4.5 billion in 2015 revenue. Those figures described continuing commercial operations, not the settlement trust’s available cash or compensation paid to recipients. [7]
The company later changed its legal name to Dow Silicones Corporation, effective February 1, 2018, according to Dow Chemical Company’s 2018 annual report. This is why later compensation litigation carries a different corporate name. Dow Corning and Dow Silicones in this history are successive names of the same corporation; neither is interchangeable with its shareholder Dow Chemical Company or former shareholder Corning Incorporated. [8]
Closing the fund did not mean every claimant was paid
An April 10, 2025 Sixth Circuit opinion affirmed termination of the funding obligations over objections from Korean claimants seeking more than $6 million. The court found the agreement’s closing conditions met: allowed claims had been paid, other filed claims had been finally resolved, and filing deadlines had passed. Crucially, final resolution included binding denials, including for documentation, address-verification or timeliness problems. It did not mean every person who sought money received it. [9]
The court rejected the argument that continued demands for payment kept the process open. Its decision concerned enforcement of the plan’s finality rules and the status of the claims before it, rather than a fresh medical trial. On October 14, 2025, the Supreme Court denied review in Korean Claimants v. Dow Silicones Corporation. Denial of review left the lower-court result in place; it was not a new ruling on implant safety. [9][10]
The long outcome was a surviving industrial business alongside a separate compensation system with limits, eligibility tests, funding schedules and an eventual endpoint. The case’s financial history lies in that separation: bankruptcy converted sprawling litigation exposure into an administered process, but the path from filing to final resolution was measured in decades. [3][9]
Sources
- Eastern District of Michigan, In re Dow Corning Corp., 187 B.R. 919 (1995), court opinion reproduced by JustiaSourceBack to text: ↑1↑2
- Federal Judicial Center, Case Studies of Mass Tort Limited Fund Class Action Settlements and Bankruptcy Reorganizations, Dow Corning chapterOfficial sourceBack to text: ↑1↑2
- Sixth Circuit, funding-agreement opinion, March 8, 2013, No. 11-2632SourceBack to text: ↑1↑2↑3
- Settlement Facility and Fund Distribution Agreement, effective June 1, 2004, Articles V–VIIOfficial source · PDFBack to text: ↑1↑2
- Institute of Medicine, Safety of Silicone Breast Implants (1999), executive-summary excerptsSourceBack to text: ↑1↑2
- FDA, Risks and Complications of Breast Implants, checked October 6, 2026Official sourceBack to text: ↑
- Dow Chemical Company, ownership restructuring completed, SEC-filed release, June 1, 2016Filing / reportBack to text: ↑
- Dow Chemical Company, 2018 Form 10-K, Dow Corning/Dow Silicones name changeFiling / reportBack to text: ↑
- Sixth Circuit, In re Settlement Facility Dow Corning Trust, April 10, 2025, No. 25-1004, court opinion reproduced by JustiaSourceBack to text: ↑1↑2↑3
- Supreme Court, October 14, 2025 order list, No. 25-128, page 7Official source · PDFBack to text: ↑